Alibaba Leads $72.7M Funding for BCI Firm StairMed

StairMed, a frontrunner in brain-computer interface (BCI) innovation, has secured a substantial RMB 500 million (approximately $72.7 million USD) in a significant funding initiative. The round was prominently led by tech giant Alibaba Group, signaling strong strategic interest in the advanced neurotechnology sector. This capital infusion propels StairMed's total funding over the past year to an impressive RMB 1.1 billion ($159.9 million USD), positioning it as a global leader and China's most heavily financed entity in the burgeoning BCI field.

The investment underscores the accelerating pace of development and commercialization within the BCI industry, a sector increasingly recognized for its potential to revolutionize medical treatment and human-computer interaction. StairMed, co-founded by Zhao Zhengtuo and Li Xue, is dedicated to creating high-performance, wireless invasive BCI systems. These systems are engineered to restore motor functions and explore advanced language reconstruction for individuals facing paralysis, directly addressing critical unmet medical needs.

This latest funding round saw participation from new investor SDIC Unity Capital, alongside robust backing from existing stakeholders including Tencent, FountainBridge Capital, OrbiMed, Oriza Seed, Qiming Venture Partners, Lilly Asia Ventures, Source Code Capital, and SSCI Leading Fund. Springhill Fund provided advisory services for the transaction.

StairMed's technological advancements are highlighted by its flagship product, the WRS02. This second-generation system features 256 channels and operates wirelessly, integrated with a proprietary surgical implantation robot. The company has already achieved critical milestones, including successful clinical implantation in human patients and validation of brain-controlled interaction capabilities. These achievements pave the way for more extensive clinical trials, with StairMed planning multicenter registration trials in 2026 involving approximately 40 participants.

The company's strategic vision extends beyond functional restoration. StairMed emphasizes the importance of accumulating comprehensive brain data, stating, "The company that accumulates the largest and richest brain datasets will be best positioned to define next-generation BCI applications and technologies." This data-centric approach aims to push the boundaries of human control and unlock novel applications for BCI technology.

This significant investment in StairMed occurs within a supportive ecosystem for BCI research and development in China. The nation's commitment to advancing brain science is evident, with a dedicated 11.6 billion yuan ($165 million) fund established to support BCI companies from research through to market entry. China's rapid ascent in the BCI domain is further solidified by the establishment of regulatory pathways for invasive neural implants, creating a fertile ground for companies like StairMed.

The successful closure of this Series C round follows StairMed's previous Series B funding of $48.5 million in February 2025, which was led by Qiming Venture Partners, OrbiMed, and Lilly Asia Ventures. The sustained investor confidence reflects the immense potential of StairMed's technology and its strategic importance in the global race to develop advanced neuro-interfacing solutions.